Last reviewed · How we verify
CJ-12420/Clarithromycin/Amoxicillin
CJ-12420 is a novel compound combined with clarithromycin and amoxicillin to provide enhanced antimicrobial activity, likely through synergistic bacterial cell wall disruption and protein synthesis inhibition.
CJ-12420 is a novel compound combined with clarithromycin and amoxicillin to provide enhanced antimicrobial activity, likely through synergistic bacterial cell wall disruption and protein synthesis inhibition. Used for Helicobacter pylori infection (eradication therapy).
At a glance
| Generic name | CJ-12420/Clarithromycin/Amoxicillin |
|---|---|
| Also known as | Lansoprazole/Clarithromycin/Amoxicillin |
| Sponsor | HK inno.N Corporation |
| Drug class | Antibiotic combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is a triple-agent combination where amoxicillin inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, clarithromycin inhibits bacterial protein synthesis by binding the 50S ribosomal subunit, and CJ-12420 (mechanism not fully disclosed in public literature) appears designed to enhance efficacy or overcome resistance. The combination targets Helicobacter pylori and other susceptible bacteria through complementary mechanisms.
Approved indications
- Helicobacter pylori infection (eradication therapy)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Allergic reactions
Key clinical trials
- A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients (PHASE3)
- To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |